Introduction: Meningiomas are the most common intracranial primary neoplasm in adults. We report 39 years-old-female with recurrent meningioma, the patient had craniotomy tumor removal 1 year ago, and the patient had second craniotomy tumor removal, and we performed an immunohistochemical staining with HER2.HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Amplification or over-expression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of cancer. Patient and observation: We report 39 years-old female with recurrent meningioma, the patient had craniotomy tumor removal 1 year ago with histopathologic result Meningothelial Meningioma (WHO Grade I) , and then the patient complain with bulging defect 6 months after surgery. CT Scan contrast shows isodens lobulated lesion, with homogeny enhancement. The patient had second craniotomy tumor removal and histopathologic result Meningothelial Meningioma (WHO Grade I), based on second pathologic result, we performed an immunohistochemical staining with HER2, we use c-erbB-2 Oncoprotein (SP3) Rabbit Monoclonal Antibody with catalog number RMAB008R manufactured by Diagnostic BioSistems. Discussion:HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Amplification or over-expression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of cancer. HER-2 is a type of oncogene in human carcinoma, and many studies have indicated HER-2 overexpression in several types of cancer and is associated with a particularly aggressive form of the disease. Conclusion: HER2 expression plays a role in the development of more-aggressive meningiomas or not is a question that needs to be clarified in further studies. The results of our case report did not advocate this role for HER2. For the HER2 targeted cancer therapy, numerous strategies including the blockage of receptor dimerization, inhibition of the tyrosine kinase activity, and interruption of the downstream signal pathway will be summarized. For the targeted drug delivery to HER2 positive tumor cells, various targeting ligands and their delivery systems will be described in details. Successful development of the humanized monoclonal anti-HER2 antibody (Trastuzumab) for the treatment of breast cancer further spurred scientists to develop various HER2 specific antibodies, dimerization inhibitors and kinase inhibitors for cancer therapy. On the other hand, the high expression of HER2 and the accessibility of its extracellular domain make HER2 an ideal target for the targeted delivery of anti-tumor drugs as well as imaging agents.
IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.
